Rui Avelar
Fortune : 3 M $ au 30/09/2026
Fortune : 3 M $ au 30/09/2026
Rui Avelar is currently Chief Medical Officer, Head-Research & Development at Evolus, Inc. since 2018.
Formerly, Dr. Avelar was Chief Medical Officer at AEON Biopharma Sub, Inc. from 2014 to 2018 and Chief Medical Officer at Allergan Medical Optics from 2011 to 2013.
Dr. Avelar earned a doctorate from the University of Toronto in 1989.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EVOLUS, INC. 0,6% | 17/04/2026 | 388 999 ( 0,6% ) | 3 M $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| EVOLUS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2014 |
| Sociétés | Poste | Fin |
|---|---|---|
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology Manufactures and wholesales pharmaceuticals | Directeur Technique/Scientifique/R&D | 01/02/2018 |
Allergan Medical Optics | Directeur Technique/Scientifique/R&D | 01/12/2013 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Evolus, Inc.
Evolus, Inc. Pharmaceuticals: MajorHealth Technology Manufactures neurotoxins | Health Technology |
University of Toronto
University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Allergan Medical Optics | Electronic Technology |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology Manufactures and wholesales pharmaceuticals | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national